New INCLUDE Project Act Mandates Lifelong Down Syndrome Research and Clinical Trial Expansion at NIH

The DeOndra Dixon INCLUDE Project Act of 2026 officially cements a dedicated research pipeline within the National Institutes of Health (NIH) specifically for Down syndrome. By adding Section 409K to the Public Health Service Act, this bill moves beyond one-off studies to establish a permanent program called the INCLUDE Project. It mandates that the NIH Director oversee high-reward research into how Trisomy 21 affects human development from birth through old age, focusing on everything from biological growth anomalies to improving daily living activities through new biomedical therapies.

A Lifespan Approach to Health

For families navigating a Down syndrome diagnosis, the medical roadmap has often felt fragmented. This bill changes that by requiring long-term "cohort studies"—basically following the same group of people over many years—to understand how the condition evolves. For example, a young adult with Down syndrome might benefit from the bill’s specific focus on co-occurring conditions like Alzheimer’s and autoimmune disorders, which appear at higher rates in this population. Section 2 of the bill directs researchers to identify "biomarkers" (biological red flags) that could lead to earlier diagnosis and more effective, concurrent treatments for these complex health issues.

Opening the Doors to Clinical Trials

One of the biggest hurdles in modern medicine is that people with intellectual disabilities are often left out of clinical trials for new drugs. This legislation explicitly pushes for the expansion of clinical trials that either include or are specifically designed for individuals with Down syndrome. This means if a new drug for heart health or cognitive function is being developed, there is now a legislative mandate to ensure this community isn't an afterthought. The bill also requires the NIH to consult with patient advocates, ensuring that the people actually living with these conditions have a seat at the table when research priorities are set.

Accountability and Cutting Red Tape

To make sure this doesn't just become another bureaucratic layer, the bill includes a built-in "anti-duplication" clause. The NIH Director must coordinate across all various institutes—like the National Institute on Aging and the National Institute of Child Health—to ensure they aren't wasting money doing the same work twice. Every two years, the NIH has to hand over a report to Congress detailing exactly what they found and, more importantly, what "real-world evidence" has been produced that doctors can actually use to treat patients. It’s a move toward transparency that aims to turn lab research into practical medical care faster than the current system allows.